IL-12, IL-18 and IFN-gamma in the immune response to bacterial infection
Lauw, F.N.

Citation for published version (APA):
Lauw, F. N. (2000). IL-12, IL-18 and IFN-gamma in the immune response to bacterial infection
Chapter 11

The CXC chemokines interferon-γ-inducible protein-10 (IP-10) and monokine induced by IFN-γ (Mig) are released during severe gram-negative bacterial infection

Fanny N. Lauw,1,2 Andrew J. H. Simpson,3,4 Jan M. Prins,2 Sander J. H. van Deventer,1 Wipada Chaowagul,5 Nicholas J. White,3,4 and Tom van der Poll1,2

Laboratory of Experimental Internal Medicine1 and Department of Infectious Diseases, Tropical Medicine and AIDS,2 Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;3 Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, U.K.;4 Sappasitprasong Hospital, Ubon Ratchathani, Thailand 5

Infect. Immun. (in press)
Chapter 11

Abstract

Interferon (IFN)-γ-inducible protein-10 (IP-10) and monokine induced by IFN-γ (Mig) are related CXC chemokines, which bind to the CXCR3 receptor and specifically target activated T lymphocytes and natural killer (NK) cells. The production of IP-10 and Mig by various cell types in vitro is strongly dependent on IFN-γ. To determine whether IP-10 and Mig are released during bacterial infection in humans, we measured plasma levels of IP-10 and Mig in patients with melioidosis, a severe gram-negative infection caused by Burkholderia pseudomallei. IP-10 and Mig were markedly elevated in patients with melioidosis on admission, particularly in blood culture-positive patients, and remained elevated during the 72-h study period. Levels of IP-10 and Mig showed a positive correlation with IFN-γ concentrations, and also correlated with clinical outcome. In whole blood stimulated with heat-killed B. pseudomallei, neutralization of IFN-γ and tumor necrosis factor-α (TNF) partly attenuated IP-10 and Mig release, while anti-interleukin-12 (IL-12) and anti-IL-18 had a synergistic effect. Stimulation with other bacteria or endotoxin also induced a strong secretion of IP-10 and Mig. These data suggest that IP-10 and Mig are part of the innate immune response to bacterial infection. IP-10 and Mig may contribute to host defense in Th1-mediated host defense during infections by attracting CXCR3+ Th1 cells to the site of inflammation.
Introduction

Chemokines are a family of small chemotactic proteins that play an important role in cell activation and migration of cells from the circulation to the site of inflammation (1, 2). On the basis of the position of their cysteine residues, chemokines are divided into several families (3). The two major families are the CC and CXC chemokine families; the latter can be further divided into two classes based on the presence of the glutamate-leucine-arginine (ELR) motif preceding the CXC sequence. The ELR-containing CXC chemokines, like interleukin-8 (IL-8), have stimulatory and chemotactic activities on neutrophils, while the non-ELR chemokines act mainly on lymphocytes.

Interferon (IFN)-γ-inducible protein-10 (IP-10) and monokine-induced by IFN-γ (Mig) are members of the non-ELR CXC chemokine family, which were discovered as products of genes inducible in response to IFN-γ (4-6). IP-10 and Mig have potent chemotactic activities and predominantly target activated T lymphocytes and natural killer (NK) cells (5, 7). IP-10 and Mig are structurally closely related, and also share a common receptor, CXCR3, which is expressed on activated T cells and NK cells, but not on monocytes or neutrophils (8). Besides their chemotactic activities, IP-10 and Mig have been shown in vitro to inhibit colony formation by hemopoietic cells (6). In mice, IP-10 and Mig inhibit neovascularization and possess anti-tumor effects (9).

IP-10 and Mig expression has been found in several animal models of infection, especially in infections where IFN-γ is known to play an important role in host defense (10, 11). In mice infected with Toxoplasma gondii or vaccinia virus, expression of Mig was strongly dependent on IFN-γ, since it was completely prevented after injection of an anti-IFN-γ mAb or in IFN-γ deficient mice (10). In contrast, IP-10 expression was not completely dependent on IFN-γ. In humans, expression of IP-10 has been demonstrated in patients with psoriasis, sarcoidosis, tuberculoid leprosy and viral meningitis (12-15). Mig expression has also been demonstrated in psoriatic lesions (16). All of these diseases are associated with increased IFN-γ production and a Th1 type immune response. Little is known of the role of IP-10 and Mig in bacterial infections.

Meliodosis is a severe infection caused by the gram-negative bacillus Burkholderia pseudomallei (17). In a murine model of melioidosis, it was shown that IFN-γ plays an essential role in host defense (18). Previously, markedly elevated plasma levels of IFN-γ have been shown in patients with melioidosis, and levels correlated with severity of disease (19, 20). After injection of endotoxin in healthy human volunteers, a well accepted model of systemic infection, plasma levels of IP-10 and Mig increase, suggesting that IP-10 and Mig are released in response to bacterial infection (21). Therefore, in the present study we measured plasma levels of IP-10 and Mig in patients with melioidosis, on admission to hospital and during a 72-h follow-up after starting antibiotic treatment. In addition, we
studied in vitro which cytokines contribute to the production of IP-10 and Mig during whole blood stimulation with heat-killed \textit{B. pseudomallei} and endotoxin (lipopolysaccharide, LPS).

\textbf{Materials and Methods}

\textbf{Patients and study design}

The patients included in the present study were also part of a previous investigation in which the release of IFN-\(\gamma\) and IFN-\(\gamma\)-inducing cytokines were studied \(\text{(20)}\), and all were part of a clinical trial comparing the efficacy of intravenous imipenem and ceftazidime in suspected severe melioidosis \(\text{(22)}\). Clinical outcomes were similar for the two treatment groups and therefore data were combined for the present investigation. Informed consent was obtained from all patients or attending relatives. The patients (aged over 14 years) were all admitted to Sappasitprason Hospital, Ubon Ratchathani, Thailand, with suspected severe melioidosis. On admission, blood, urine and throat swab specimens, plus, where available, specimens of sputum and pus, were collected for culture. Clinical data (and baseline APACHE II score) were recorded at study entry. Blood samples (EDTA-anticoagulated) were collected directly before the start of antibiotic treatment \((t=0)\), and at 12, 24, 48, and 72 h thereafter. In addition, blood was collected from 12 healthy adult volunteers (patients’ relatives or hospital staff, all resident in Ubon Ratchathani or the surrounding provinces). Plasma was separated immediately and stored at \(-70^\circ\text{C}\) until assays were performed.

\textbf{Whole blood stimulation}

Heat-killed \textit{B. pseudomallei}, \textit{Pseudomonas aeruginosa}, \textit{Escherichia coli}, \textit{Streptococcus pneumoniae} and \textit{Staphylococcus aureus} were prepared from clinical isolates. Each isolate was suspended in culture medium and incubated overnight in 5\% \(\text{CO}_2\) at 37\(^\circ\text{C}\). This suspension was diluted in fresh medium the next morning and incubated until log-phase growth was obtained. Thereafter, 10-fold dilutions of this suspension were made and plated on blood agar plates for colony-forming unit (CFU) counts. Bacteria were harvested by centrifugation, washed twice in pyrogen-free 0.9\% NaCl, resuspended in 20 ml 0.9\% NaCl, and heat inactivated for 60 minutes at 80\(^\circ\text{C}\). A 500-\(\mu\text{l}\) sample on a blood agar plate did not show growth of bacteria.

Whole blood was collected from 6 healthy individuals aseptically using a sterile collecting system consisting of a butterfly needle connected to a syringe (Becton Dickinson & Co, Rutherford, NJ). Anticoagulation was obtained using endotoxin-free heparin (Leo Pharmaceutical Products B.V., Weesp, the Netherlands; final concentration 10 U/ml blood).
Whole blood, diluted 1:1 in pyrogen-free RPMI 1640 (Bio Wittaker, Verviers, Belgium), was stimulated for 24 h at 37°C with $10^7$ CFU/ml heat-killed bacteria in the presence or absence of mouse anti-human TNF (MAK 195; final concentration 10 µg/ml), anti-IFN-γ, anti-IL-12 and anti-IL-18 (all mouse IgG, R&D Systems, Abingdon, United Kingdom; final concentration all 10 µg/ml). MAK 195F was generously provided by Knoll AG, Ludwigshafen, Germany. During in vitro cell stimulation, these concentrations of the monoclonal Abs (mAbs) completely neutralize activity of recombinant human TNF (rhTNF), rhIFN-γ, rhIL-12 and rhIL-18 when added at 1-2 log higher concentrations compared to levels detected after whole blood stimulation with heat-killed *B. pseudomallei* (20) (information on the neutralizing capacities of the mAbs used provided by the manufacturer). Control mouse IgG (R&D Systems) was used in the appropriate concentrations. After the incubation, supernatant was obtained after centrifugation and stored at -20°C until assays were performed.

**Assays**

IP-10 and Mig levels were measured by ELISA according to the instructions of the manufacturer. In short, mouse anti-human IP-10 (4 µg/ml) and mouse anti-human Mig (1 µg/ml) were used as coating Abs, biotinylated goat anti-human IP-10 (50 ng/ml) and goat anti-human Mig (4 µg/ml) as detection Abs, and recombinant human IP-10 and Mig as standards. All IP-10 reagents were from R&D Systems (Abingdon, UK), and all Mig reagents from PharMingen (San Diego, CA). The detection limits of the assays were 20 pg/ml (IP-10) and 8 pg/ml (Mig).

**Statistical analysis**

Values in patients are given as medians and ranges. Differences between controls and/or patient groups were analyzed by the Mann-Whitney U test. Changes in time during antibiotic treatment were analyzed by one-way ANOVA. These two tests were performed after log transformation of the data. Spearman's $\rho$ was used to determine correlation coefficients. Data of the in vitro stimulations are expressed as mean ± SE of six donors. Statistical analysis was performed by Wilcoxon test. $P < 0.05$ was considered to represent a significant difference.
Chapter 11

Results

Patients

The characteristics of this patient population have been reported previously (20). Briefly, a total of 86 consecutive patients (43 males, 43 females) with a median age of 50 years (range 16-85 years) were studied. In 64 patients, the diagnosis of melioidosis was confirmed by positive cultures for B. pseudomallei. Positive blood cultures were found in 34 patients (of whom 16 patients died), while in the other 30 patients, B. pseudomallei was isolated only from sites other than blood (2 died). The remaining 22 patients were not culture-positive for B. pseudomallei (and are referred to subsequently as patients with diseases other than melioidosis). 15 of these patients were diagnosed with other infections: clinical sepsis in 9 patients (of whom 4 died) with positive blood cultures in 4 patients (E. coli, Klebsiella pneumoniae, P. aeruginosa and S. aureus), pneumonia in 2 patients (positive cultures for S. aureus in 1 patient, who died), urinary tract infection in 1 patient and tuberculosis in 3 patients. In 3 patients, liver and/or splenic abscesses without positive cultures were found, 1 patient was diagnosed with hepatocellular carcinoma, while in 3 patients no final diagnosis was made (1 died). Median APACHE II score in patients with bacteremic melioidosis was 16 (4-30), in the non-bacteremic melioidosis patients 9.5 (1-24) and in the group with diseases other than melioidosis 13.5 (5-24).

IP-10 and Mig concentrations on admission

Median plasma concentrations of IP-10 in healthy controls were 352 (range 61-821) pg/ml (Fig. 1). In patients with melioidosis, markedly elevated levels of IP-10 were found compared to controls (P < 0.001), with significantly higher concentrations in patients with positive blood cultures (5923 [282-31,713] pg/ml) than in patients with non-bacteremic melioidosis (1511 [230-27,355] pg/ml; P < 0.001). In patients with bacteremic melioidosis, levels of IP-10 were higher in patients who died then in patients who survived (9545 [282-31,713] pg/ml vs. 2924 [703-11,996] pg/ml; P = 0.004). IP-10 plasma concentrations correlated positively with APACHE II scores (r = 0.64; P < 0.001). In patients with diseases other than melioidosis, IP-10 levels were increased compared to controls (965 [103-93,732] pg/ml; P = 0.001), but significantly lower than in patients with bacteremic melioidosis (P = 0.015). IP-10 concentrations were higher in non-surviving patients than in surviving patients (7,986 [839-93,732] pg/ml and 832 [103-12,174] pg/ml respectively; P = 0.018).

Mig was detectable in plasma of healthy controls at a median concentration of 914 (220-2772) pg/ml (Fig. 1). Mig concentrations were markedly increased in melioidosis patients (P < 0.001), with higher levels in patients with positive blood cultures then in patients with non-bacteremic melioidosis (18,265 [1185-407,000] pg/ml and 5,036 [1017-
IP-10 and Mig release in melioidosis

167,000) pg/ml respectively; P < 0.001). Patients with positive blood cultures who died had higher Mig plasma concentrations compared to patients who survived (27,761 (1185-407,000) pg/ml and 9409 (1330-46,024) pg/ml respectively; P = 0.001). Mig levels showed a positive correlation with APACHE II scores (p = 0.72; P < 0.001). In patients with other diseases than melioidosis, Mig concentrations were elevated compared to controls (4425 (717-172,000) pg/ml; P < 0.001), although significantly lower than in bacteremic melioidosis patients (P = 0.043), with higher levels in patients who died than in patients who survived (24,310 (4425-172,000) pg/ml and 2880 (717-69,791) pg/ml respectively; P = 0.008).

Figure 1. Plasma concentrations of IP-10 and Mig on admission in patients with culture-proven melioidosis, in patients with diseases other than melioidosis and in healthy controls. Horizontal lines represent medians. * indicates P < 0.05 vs. controls. P-values reflect differences between groups by Mann-Whitney U test.

In patients with culture-proven melioidosis and also in the total patient population, IP-10 and Mig plasma levels showed a strong positive correlation (Table 1). Since the production of IP-10 and Mig is strongly IFN-γ dependent in both in vitro and mouse studies, we examined correlations between both IP-10 and Mig concentrations and IFN-γ levels in these patients (the IFN-γ levels have been reported previously (20)). Both IP-10 and Mig showed a positive, although weak, correlation with IFN-γ (Table 1).
Table 1. Correlations between IP-10, Mig and IFN-γ on admission in patients with clinically suspected melioidosis.

<table>
<thead>
<tr>
<th>Correlation</th>
<th>Patients with melioidosis (n=64)</th>
<th>Total patient population (n=86)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( \rho )</td>
<td>( \rho )</td>
</tr>
<tr>
<td>IP-10 - Mig</td>
<td>0.88</td>
<td>0.87</td>
</tr>
<tr>
<td>IP-10 - IFN-γ</td>
<td>0.49</td>
<td>0.51</td>
</tr>
<tr>
<td>Mig - IFN-γ</td>
<td>0.44</td>
<td>0.52</td>
</tr>
</tbody>
</table>

**IP-10 and Mig during follow-up**

Patients with culture-proven melioidosis were followed for 72 h following the start of antibiotic therapy with either ceftazidime or imipenem. Since the type of antibiotic treatment had no effect on IP-10 and Mig levels, data of the two treatment groups were combined (data not shown). In patients with positive blood cultures for *B. pseudomallei*, both IP-10 and Mig concentrations decreased significantly in time during antibiotic treatment (72 h: IP-10: 2,328 (200-11,885) pg/ml, Mig: 4893 (993-23,606) pg/ml; \( P = 0.029 \) and \( P = 0.009 \) respectively) (Fig. 2). However, IP-10 and Mig levels at 72h after the start of antibiotic therapy were still elevated compared to levels in healthy controls (both \( P < 0.001 \)). In patients with non-bacteremic melioidosis, IP-10 and Mig concentrations did not significantly decrease in time during antibiotic treatment, and remained elevated until the end of the 72-h study period (data not shown).

![Plasma levels of IP-10 and Mig in patients with bacteremic melioidosis during antibiotic treatment. Horizontal lines represent medians. P-values indicate changes in time analyzed by one-way analysis of variance.](image-url)

**Figure 2.** Plasma levels of IP-10 and Mig in patients with bacteremic melioidosis during antibiotic treatment. Horizontal lines represent medians. P-values indicate changes in time analyzed by one-way analysis of variance.
Regulation of IP-10 and Mig production in whole blood

The production of IP-10 and Mig by various cell types in vitro is strongly dependent on IFN-γ (23, 24). Also, co-stimulation with TNF was needed for optimal IFN-γ-induced IP-10 and Mig release by human neutrophils (24). Melioidosis is associated with elevated plasma concentrations of several proinflammatory cytokines (19, 20, 25). To obtain insight into the role of endogenous cytokines in IP-10 and Mig release during melioidosis, we incubated whole blood with heat-killed *B. pseudomallei* (amount equivalent to $10^7$ CFU/ml), in the presence of neutralizing antibodies against cytokines which are important for IP-10 and Mig release and which are known to be important in the pathogenesis of melioidosis. Incubation of whole blood for 24 h at 37°C without heat-killed *B. pseudomallei* resulted in detectable levels of IP-10 (299 ± 94 pg/ml) and Mig (352 ± 109 pg/ml). Incubation with heat-killed *B. pseudomallei* increased IP-10 levels to 4448 ± 955 pg/ml and Mig levels to 3851 ± 650 pg/ml (both *P* < 0.05 vs. control). Addition of control IgG did not influence IP-10 and Mig concentrations. Addition of either anti-IFN-γ or anti-TNF decreased the release of IP-10 significantly and, more potently, that of Mig (Table 2). In contrast, anti-IL-12 or anti-IL-18 alone did not significantly inhibit IP-10 or Mig production, but the combination of anti-IL-12 and anti-IL-18 resulted in a synergistic inhibition of both IP-10 and Mig release. Addition of both anti-IFN-γ and anti-IL-12 induced a further decrease in IP-10 and Mig production relative to the addition of anti-IFN-γ only, while the combination of anti-IFN-γ and anti-IL-18 had no additional inhibitory effect.

Table 2. Effects of neutralizing mAbs against proinflammatory cytokines on IP-10 and Mig production during whole blood stimulation with heat-killed *B. pseudomallei* or *E. coli* LPS.

<table>
<thead>
<tr>
<th>% inhibition</th>
<th>IP-10</th>
<th>Mig</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. pseudomallei</strong></td>
<td><strong>LPS</strong></td>
<td><strong>B. pseudomallei</strong></td>
</tr>
<tr>
<td>anti-IFN-γ</td>
<td>19.0 ± 6.2 *</td>
<td>50.2 ± 5.5 *</td>
</tr>
<tr>
<td>anti-IL-12</td>
<td>4.3 ± 5.9</td>
<td>59.1 ± 3.9 *</td>
</tr>
<tr>
<td>anti-IL-18</td>
<td>0.6 ± 7.2</td>
<td>26.1 ± 6.2 *</td>
</tr>
<tr>
<td>anti-TNF</td>
<td>22.1 ± 1.1</td>
<td>36.7 ± 3.6 *</td>
</tr>
<tr>
<td>anti-IL-12 + anti-IL-18</td>
<td>28.4 ± 5.4 *</td>
<td>65.0 ± 2.5</td>
</tr>
<tr>
<td>anti-IFN-γ + anti-IL-12</td>
<td>33.8 ± 5.9 *</td>
<td>ND</td>
</tr>
<tr>
<td>anti-IFN-γ + anti-IL-18</td>
<td>21.3 ± 7.5 *</td>
<td>ND</td>
</tr>
</tbody>
</table>

Data are mean ± SE of 6 healthy donors and expressed as percentage inhibition relative to incubation with heat-killed *B. pseudomallei* only. Whole blood, diluted 1:1 in RPMI, was stimulated for 24 h at 37°C with 107 CFU/ml heat-killed *B. pseudomallei* or LPS (10 ng/ml) in the presence or absence of neutralizing Abs against TNF, IFN-γ, IL-12, or IL-18 (final concentration all 10 μg/ml). Incubation without stimulus resulted in low levels of IP-10 (653 ± 110 pg/ml) and Mig (253 ± 96 pg/ml). IP-10 levels after stimulation with heat-killed *B. pseudomallei* were 4,448 ± 955 pg/ml, Mig levels were 3,851 ± 650 pg/ml. Stimulation with LPS increased IP-10 concentrations to 12,594 ± 1686 pg/ml, and Mig levels to 2858 ± 807 pg/ml. * indicates *P* < 0.05 vs. control Ab. # indicates *P* < 0.05 vs. anti-IFN-γ. ND = not determined.
We have shown previously that plasma levels of IP-10 and Mig increase after an i.v. bolus injection of LPS in humans (21). In accordance with these results, incubation of whole blood with LPS resulted in elevated concentrations of IP-10 (12,594 ± 1686 pg/ml) and Mig (2858 ± 807 pg/ml; both P < 0.05 vs. control). In contrast to the results found with heat-killed B. pseudomallei, addition of anti-IL-12 strongly inhibited IP-10 and Mig release, while anti-IL-18 also significantly attenuated IP-10 and Mig release, although to a lesser extent than anti-IL-12 (Table 2). The combination of anti-IL-12 and anti-IL-18 further decreased slightly the release of IP-10 and Mig, although this difference was not significant compared to the effect of anti-IL-12 only. Addition of anti-IFN-γ strongly inhibited LPS-induced IP-10 and Mig release, while anti-TNF also had a strong inhibitory effect (Table 2).

To determine whether other bacteria can stimulate the release of IP-10 and Mig, we compared the effect of heat-killed B. pseudomallei with other gram-negative bacteria (i.e. heat-killed P. aeruginosa and E. coli) and gram-positive bacteria (heat-killed S. pneumoniae and S. aureus) during whole blood stimulation in vitro. As shown in Table 3, all bacteria were potent inducers for IP-10 and Mig production.

**Table 3.** IP-10 and Mig release during whole stimulation with different bacteria.

<table>
<thead>
<tr>
<th>Heat-killed bacteria (10^7 CFU/ml)</th>
<th>IP-10 (pg/ml)</th>
<th>Mig (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. pseudomallei</td>
<td>6299 ± 836</td>
<td>1794 ± 282</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>4171 ± 701</td>
<td>1903 ± 449</td>
</tr>
<tr>
<td>E. coli</td>
<td>7005 ± 619</td>
<td>2328 ± 386</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>2899 ± 992</td>
<td>3379 ± 1659</td>
</tr>
<tr>
<td>S. aureus</td>
<td>10,444 ± 1800</td>
<td>3247 ± 569</td>
</tr>
</tbody>
</table>

Data are mean ± SE of 6 healthy subjects. Whole blood, diluted 1:1 in RPMI, was stimulated for 24 h at 37°C with different heat-killed bacteria (final concentration 10^7 CFU/ml). Incubation of whole blood for 24 h at 37°C without bacteria resulted in detectable levels of IP-10 (963 ± 344 pg/ml) and Mig (352 ± 109 pg/ml).

**Discussion**

IP-10 and Mig are members of the non-ELR CXC chemokine family, which are potent chemoattractants for activated T lymphocytes and NK cells (6). They were identified as products of genes induced in response to IFN-γ (4, 5). The production of IP-10 and Mig can be induced strongly by IFN-γ in a large variety of cells in vitro, including monocytes/macrophages, neutrophils, epithelial cells and endothelial cells (6, 23, 24, 26).
In murine infection models, expression of IP-10 and Mig has been demonstrated in multiple organs, and was largely dependent on IFN-γ (10). Increased expression of IP-10 and Mig has been observed in various clinical conditions in humans (12-16), but little is known of the expression of IP-10 and Mig, and their relation to IFN-γ, during bacterial infection.

In this study we have demonstrated that plasma concentrations of IP-10 and Mig are elevated markedly and for a prolonged time in patients with a melioidosis. Melioidosis is a severe infection caused by the gram-negative bacillus *B. pseudomallei* and an important cause of illness and death in parts of Southeast Asia (17). This patient population was selected since IFN-γ was shown to be important for host defense in a mouse model of melioidosis (18). In addition, elevated plasma levels of IFN-γ have been found in a high proportion of patients with melioidosis (19, 20). The clinical presentation of melioidosis varies from mild localized disease to acute fulminant septicemia. IP-10 and Mig concentrations were higher in patients with bacteremic disease, and higher levels were associated with a fatal outcome. Concentrations of IP-10 and Mig showed a positive, although weak, correlation with IFN-γ levels. These data indicate that during severe melioidosis, IP-10 and Mig levels correlate with severity of disease and with IFN-γ levels, although this latter correlation was not as strong as previously found *in vitro* and in mice (10, 24, 26).

Most chemokines can bind to more than one chemokine receptor, but IP-10 and Mig specifically bind to the CXCR3 (3, 8). Another recently identified non-ELR CXC chemokine, IFN-γ-inducible T cell α chemoattractant (I-TAC), also selectively binds to CXCR3 (27). CXCR3 is only expressed on activated T lymphocytes and NK cells, and not on other leukocytes (8). Recently, it has been demonstrated that CXCR3 (and CCR5) is preferentially expressed on Th1 type lymphocytes (28-30). A Th1-type immune response is associated with the release of Th1 type cytokines like IFN-γ and IL-2, and known to enhance cell-mediated immunity, which is important for host defense against intracellular pathogens (31). *In vitro* studies have demonstrated that *B. pseudomallei* can survive intracellularly within phagocytes (32). This suggests that during melioidosis, IP-10 and Mig may be important for the activation and attraction of CXCR3+ Th1 cells to the site of inflammation, which can contribute to host defense against *B. pseudomallei* by the additional production of Th1 type cytokines.

To obtain more insight into the role of IFN-γ in the regulation of IP-10 and Mig production during bacterial infection, we incubated whole blood with heat-killed *B. pseudomallei* and LPS in the presence or absence of neutralizing antibodies against IFN-γ. Interestingly, neutralization of IFN-γ only reduced the release of IP-10 and Mig slightly. The effect of anti-IFN-γ on Mig release was stronger than the effect on IP-10 production. This is concordant with previous studies, which demonstrated that Mig release is more
dependent on IFN-γ than IP-10 production (6, 10). These data suggest that the effect of *B. pseudomallei* on IP-10 and Mig production is not completely dependent on IFN-γ.

To study the involvement of other cytokines, we performed whole blood stimulations with neutralizing Abs against a number of cytokines that are elevated in patients with melioidosis, i.e. TNF, IL-12 and IL-18 (20, 25). TNF has been shown to play an essential synergistic role with IFN-γ in the production IP-10 and Mig production in vitro (24, 26). In line with these results, addition of anti-TNF significantly inhibited heat-killed *B. pseudomallei*-stimulated IP-10 and Mig production. IL-12 is a potent stimulator of IFN-γ production, and IL-18 synergistically enhances IL-12-induced IFN-γ release (33, 34). Previously, we found that addition of anti-IL-12 or anti-IL-18 strongly, but not completely, inhibited IFN-γ production during whole blood stimulation with heat-killed *B. pseudomallei* (20), which may explain why neither anti-IL-12 nor anti-IL-18 alone had any effect. The combination of anti-IL-12 and IL-18 had an additional inhibitory effect on IFN-γ production, which may have provided a sufficient decrease in IFN-γ production to inhibit IP-10 and Mig release. The combination of anti-IL-12 and anti-IFN-γ had an additional inhibitory effect, suggesting that IL-12 and IFN-γ influence IP-10 and Mig production in part by independent mechanisms. In contrast to the effects on heat-killed *B. pseudomallei*-stimulated IP-10 and Mig production, neutralization of IFN-γ or TNF strongly inhibited LPS-induced IP-10 and Mig release, while anti-IL-12 and anti-IL-18 also had a potent inhibitory effect. This suggests that the stimulatory effect of *B. pseudomallei* on IP-10 and Mig production is only partially mediated through LPS, and is consistent with previous studies which suggest that *B. pseudomallei* endotoxin is considerably less potent than LPS from *E. coli* (35).

In conclusion, we found that during severe gram-negative bacterial infection in humans, IP-10 and Mig plasma concentrations were elevated markedly, and correlated with the severity of disease and clinical outcome. In whole blood in vitro, not only *B. pseudomallei*, but also other gram-negative and gram-positive bacteria, as well as *E. coli* LPS were able to induce IP-10 and Mig release. These data suggest that the release of IP-10 and Mig is part of the innate immune response to bacterial infection. IP-10 and Mig may contribute to Th1-mediated host defense during infections by attracting CXCR3+ Th1 cells to the site of inflammation.

**Acknowledgements**
The clinical component of the study was part of the Wellcome-Mahidol University Oxford Tropical Medicine Research Programme, supported by the Wellcome Trust of Great Britain.

We thank the Director of Sappasitprasong Hospital for his continued support, and the Medical and Nursing staff of the Department of Medicine for their help. Drs Yupin Suputtamongkol, Mike Smith and Brian Angus helped with collection of specimens.
**IP-10 and Mig release in melioidosis**

**References**

Chapter 11


